• BIMZELX[®] (bimekizumab) approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma

    Monday January 24th 2022

  • argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

    Friday January 21st 2022

  • Cerba Healthcare enters agreement to acquire Viroclinics-DDL

    Thursday January 20th 2022

  • Ann Van Gysel wordt CEO van flanders.healthTech

    Thursday January 20th 2022

  • KU Leuven kiest met Open Data-aanpak resoluut voor Open Wetenschap

    Thursday January 20th 2022

  • Jyseleca®▼ (Filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

    Wednesday January 19th 2022

  • Mithra announces positive top-line results from Donesta® Phase 3 studies in menopausal women

    Friday January 14th 2022

  • BioStrand secures second VLAIO research grant

    Thursday January 13th 2022

  • Your news here?

  • Biotalys and Olon enter into long-term partnership for the production of protein-based biocontrols

    Wednesday January 12th 2022

  • Biohaven enters exclusive license and research collaboration agreement with KU Leuven to advance first-in-class TRPM3 antagonists for the treatment of pain

    Wednesday January 12th 2022

  • Oxurion provides update on clinical pipeline progress

    Friday January 7th 2022


Strategic Partners